Adil I Daud

29PUBLICATIONS
127CO-AUTHORS
Predictive and prognostic markersMedical infection agents (incl. prions)Gene expression (incl. microarray and other genome-wide approaches)Molecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Sep 05, 2026
A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines.

|May 18, 2026
Lipid Nanoparticle-Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

|Jan 21, 2026
PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.

Sixuan Pan, Inés Fernández-Maestre, Kai-Chun Chang

|Aug 03, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.

Mohammed M Milhem, Yousef Zakharia, Diwakar Davar

|Mar 05, 2025
Single-Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T-cell Subpopulation That Is Correlated with Response to Checkpoint Therapy in Melanoma.

Kelly M Mahuron, Osmaan Shahid, Prachi Sao

|Nov 08, 2024
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response.

Zoe Quandt, Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah

Pageof 5

Frequent Collaborators

3 joint publications

Robert H Pierce

2 joint publications

Kelly M Mahuron

2 joint publications

Alain P Algazi

2 joint publications

Katy K Tsai